Istradefylline

Istradefylline is a medication used to manage Parkinson's disease. It is a selective adenosine A2A receptor antagonist. It works by blocking the action of adenosine at A2A receptors in the brain. These receptors are found in areas involved in motor control, and blocking them can help to improve the motor symptoms of Parkinson's disease. Istradefylline is typically used as an add-on therapy to levodopa and carbidopa in patients experiencing "off" episodes, which are periods when Parkinson's medication is less effective.

The development of istradefylline aimed to provide an alternative or complementary treatment for Parkinson's disease symptoms. Clinical trials have investigated its efficacy in reducing "off" time and improving motor function in patients with Parkinson's disease. It is administered orally. The most common side effects reported include involuntary movements (dyskinesia), insomnia, and nausea. It is important for patients to discuss potential risks and benefits with their healthcare provider. Istradefylline is not a cure for Parkinson's disease but is intended to help manage its symptoms and improve the quality of life for affected individuals.